Sertraline May Improve Language Developmental Trajectory in Young Children with Fragile X Syndrome: A Retrospective Chart Review
Year: 2012
Type: article
Study design: Observational Study
Abstract: Young children with fragile X syndrome (FXS) often experience anxiety, irritability, and hyperactivity related to sensory hyperarousal. However, there are no medication recommendations with documented efficacy for children under 5 years old of age with FXS. We examined data through a chart review for 45 children with FXS, 12-50 months old, using the Mullen Scales of Early Learning (MSEL) for baseline and longitudinal assessments. All children had clinical level of anxiety, language delays based on MSEL scores, and similar early learning composite (ELC) scores at their first visit to our clinic. Incidence of autism spectrum disorder (ASD) was similar in both groups. There were 11 children who were treated with sertraline, and these patients were retrospectively compared to 34 children who were not treated with sertraline by chart review. The baseline assessments were done at ages ranging from 18 to 44 months (mean 26.9, SD 7.99) and from 12 to 50 months (mean 29.94, SD 8.64) for treated and not treated groups, respectively. Mean rate of improvement in both expressive and receptive language development was significantly higher in the group who was treated with sertraline (P < 0.0001 and P = 0.0071, resp.). This data supports the need for a controlled trial of sertraline treatment in young children with FXS.
Source: Autism Research and Treatment
DOI: 10.1155/2012/104317
Authors: Tri Indah Winarni, Weerasak Chonchaiya, Evan Adams, Jacky Au, Yi Mu, Susan M. Rivera, Danh V. Nguyen, Randi J. Hagerman
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $800
Funders: National Institutes of Health, Health Resources and Services Administration, University of California, Davis, National Institute on Aging, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Dental and Craniofacial Research, National Center for Research Resources, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: G1184855618, G1898880685, G2163302634, G2183559457, G2335821925, G2738306040, Development of targeted therapeutic agents for the treatment of FXTAS (2 of 6), Characterization and Treatment of CNS Abnormalities in Premutation Carriers (4 of, Neuro Therapeutics Research Institute (1 of 6), G3566507055, G360721996, G3746498070, G3777162036, G3876448596, G3890775050, G3929748281, G4037113195, UC Davis Clinical and Translational Science Center, G44094036, G4637982368, G5091678919, G5178656058, Research in Intellectual and Developmental Disabilities, Interdisciplinary Training Program in Neurotherapeutics (6 of 6), G6107062629, G6464695680, G6719544525, G7067410900, G7161627521, Trajectories and Markers of Neurodegeneration in Fragile X Premutation Carriers, G7418573391, G8312324571, G8340852147, G9000159210, Genotype-Phenotype Relationships in Fragile X Families
OpenAlex ID: W2007289008